Urological cancer constitutes approximately 30% of all cancer occurring in the Third
and Second Worlds. In the main, these diseases are caused by environmental factors,
such as diet and smoking, and it is hoped that action to regulate the influence of
these environmental pathogens will lead to a decreased incidence over the next two
or three decades.
In the meantime, our understanding of the scientific basis for urothelial malignancy
has broadened significantly. For example, studies in prostate cancer, which
were few and far between 20 years ago, have increased, and the degree of government
intervention, both in Europe and the United States, to support work in this
field has grown significantly as a result of patient pressure. Interest too has increased
from the pharmaceutical industry, and this has led to the development of new treatment
options for all of the urological malignancies and real improvements in remission
rates and durations.
This book summarizes developments in all areas of urological cancer, including
clinical and molecular advances.